SCHEMBL13824477

SCHEMBL13824477

OC1(c2ccc(Cl)cc2)CCN(CC/C=C2/c3cc(Cl)ccc3OCc3ncccc32)CC1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR1 P32246 6/20 0.66
CHRM2 P08172 1/20 0.54
CCR5 P51681 1/20 0.54
DRD2 P14416 3/20 0.41
USP2 O75604 1/20 0.40
LMNA P02545 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
HTR1A P08908 1/20 0.40
ADRA2A P08913 1/20 0.40
CYP2D6 P10635 1/20 0.40
ADRA2B P18089 1/20 0.40
ADRA2C P18825 1/20 0.40
SLC6A2 P23975 1/20 0.40
HTR2A P28223 1/20 0.40
HTR2C P28335 1/20 0.40
SLC6A4 P31645 1/20 0.40
CYP2C19 P33261 1/20 0.40
ADRA1A P35348 1/20 0.40
HRH1 P35367 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14419959 1.00 CCR1 (0.66) CCR1CHRM2CCR5DRD2USP2
SCHEMBL7206932 0.94 CCR1 (0.64) CCR1CHRM2CCR5DRD2OPRM1
SCHEMBL7206934 0.94 CCR1 (0.64) CCR1CHRM2CCR5DRD2OPRM1
SCHEMBL10288263 0.93 CCR1 (0.63) CCR1CHRM2CCR5DRD2HTR1A
SCHEMBL13824314 0.93 CCR1 (0.63) CCR1CHRM2CCR5DRD2OPRM1
SCHEMBL10287601 0.93 CCR1 (0.63) CCR1CHRM2CCR5DRD2LMNA
SCHEMBL18895949 0.93 CCR1 (0.65) CCR1CHRM2CCR5DRD2DRD3
SCHEMBL7205645 0.93 CCR1 (0.61) CCR1CHRM2CCR5DRD2HTR1A
SCHEMBL7205649 0.93 CCR1 (0.61) CCR1CHRM2CCR5DRD2HTR1A
SCHEMBL12121530 0.92 CCR1 (0.63) CCR1CHRM2CCR5DRD2HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7541365-B2 Chemokine receptor antagonists and methods of use therefor MILLENNIUM PHARMACEUTICALS, INC. (US) 2009-06-02 US disclosed
US-20070060592-A1 heterocylic amines such as 2-(5-{3-[4-(4-Chloro-2-methyl-phenyl)-piperazin-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl)-propan-2-ol, used for treating diseases associated with aberrant leukocyte recruitment and/or activation MILLENNIUM PHARMACEUTICALS, INC. 2007-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070060592-A1 heterocylic amines such as 2-(5-{3-[4-(4-Chloro-2-methyl-phenyl)-piperazin-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl)-propan-2-ol, used for treating diseases associated with aberrant leukocyte recruitment and/or activation THPO, NFATC1, HPGDS CCR1 19/4885CHRM2 615/4885CCR5 55/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.